Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun 1;177(6):784-791.
doi: 10.1001/jamainternmed.2017.0212.

Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis

Raseen Tariq  1 , Siddharth Singh  2 , Arjun Gupta  3 , Darrell S Pardi  1 , Sahil Khanna  1
Affiliations
Meta-Analysis

Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis

Raseen Tariq et al. JAMA Intern Med. .

Abstract

Importance: Gastric acid suppression has been associated with an increased risk of primary Clostridium difficile infection (CDI), but the risk of recurrent CDI in patients taking gastric acid suppressant medications is unclear.

Objective: To perform a systematic review and meta-analysis to evaluate the association between gastric acid suppressants and recurrent CDI.

Data sources: MEDLINE, EMBASE, the Cochrane Central Register, the Cochrane Database, and Web of Science were searched from January 1, 1995, to September 30, 2015, for studies assessing the association between gastric acid suppressant exposure and recurrent CDI. Search terms included Clostridium difficile, pseudomembranous colitis, proton pump inhibitor, and histamine H2 blocker.

Study selection: Case-control studies, cohort studies, and clinical trials that included patients with CDI who did or did not receive gastric acid suppressant therapy and who were evaluated for recurrent CDI were included, with no restriction on study setting (inpatient or outpatient).

Data extraction and synthesis: The Newcastle-Ottawa scale was used to assess the methodologic quality of included studies. In this scale, case-control and cohort studies were scored on selection, comparability, and ascertainment of the outcome of interest. Data were independently abstracted to a predetermined collection form by 2 investigators. Summary odds ratio estimates with 95% CIs were calculated using the random-effects model and software to calculate the pooled effect size of studies reporting multivariate analyses.

Main outcomes and measures: Risk of recurrent infection in patients with CDI and its association with use of gastric acid suppressant medication.

Results: Sixteen observational studies were included, together reporting 7703 patients with CDI; among these, 1525 patients (19.8%) developed recurrent CDI. The rate of recurrent CDI in patients with gastric acid suppression was 22.1% (892 of 4038 patients) compared with 17.3% (633 of 3665) in patients without gastric acid suppression, which indicated an increased risk by meta-analysis (odds ratio [OR], 1.52; 95% CI, 1.20-1.94; P < .001). There was significant heterogeneity among the studies, with an I2 value of 64%. Subgroup analyses of studies adjusting for age and potential confounders confirmed an increased risk of recurrent CDI with use of gastric acid suppressants (OR, 1.38; 95% CI, 1.08-1.76; P = .02).

Conclusions and relevance: Meta-analyses of observational studies suggest that patients who receive gastric acid suppressants may be at increased risk for recurrent CDI. These data should be interpreted with caution because they may be confounded owing to the observational design of the individual studies. It may be reasonable to re-evaluate the need for these medications in patients with CDI.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Flow Diagram of Study Selection Process
CDI indicates Clostridium difficile infection.
Figure 2.
Figure 2.. Analysis of All Studies
Increased odds of recurrent Clostridium difficile infection (CDI) with gastric acid suppressants shown by the random-effects model.
Figure 3.
Figure 3.. Publication Bias
No evidence of publication bias was noted. M-H indicates Mantel-Haenszel test; OR, odds ratio.
Figure 4.
Figure 4.. Nine Studies That Controlled for Potential Confounders
Plot demonstrates increased risk of recurrent Clostridium difficile infection with gastric acid suppressants by the random-effects model (odds ratio, 1.38; 95% CI, 1.08-1.76).
See this image and copyright information in PMC

Comment in

References

    1. Magill SS, Edwards JR, Bamberg W, et al. ; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team . Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370(13):1198-1208. - PMC - PubMed
    1. Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol. 2014;7(2):72-86. - PMC - PubMed
    1. Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C difficile Surveillance Team Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369-2370. - PMC - PubMed
    1. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4(4):409-416. - PubMed
    1. Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87(11):1046-1053. - PMC - PubMed

MeSH terms

Substances